THOMAS FERRARI: Open Payments
NPI 1346249109 · SWAINSBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$519 in 27 payments from 12 companies in 2025. Trend: 2023 $266 · 2024 $327 · 2025 $519
Food & beverage: $474Education: $45
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $176 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Lilly USA, LLC | 2 | $63 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Novo Nordisk Inc | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
Products named: VRAYLAR, FANAPT, QULIPTA, ENTRESTO, FARXIGA, Ozempic, AJOVY, CAPLYTA.
Industry payments across GA — which companies pay providers there.
